Henry Ford Hospital Medical Journal


Percutaneous absorption of betamethasone-17-benzoate, a new topical corticosteroid, was sufficient enough to result in adrenocortical suppression in patients with psoriasis or atopic dermatitis when 0.025% of the steroid cream was applied under occlusion to 30% or more of the body surface, using 9 gm or more of the preparation. The adrenal function returned to normal within a short time after the cream was discontinued.